FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Bekaii-Saab, Tanios S; Valle, Juan W; Van Cutsem, Eric; Rimassa, Lorenza; Furuse, Junji; Ioka, Tatsuya; Macarulla Mercadé, Teresa

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Bekaii-Saab, Tanios S
dc.contributor.author	Valle, Juan W
dc.contributor.author	Van Cutsem, Eric
dc.contributor.author	Rimassa, Lorenza
dc.contributor.author	Furuse, Junji
dc.contributor.author	Ioka, Tatsuya
dc.contributor.author	Macarulla Mercadé, Teresa
dc.date.accessioned	2021-11-17T13:14:07Z
dc.date.available	2021-11-17T13:14:07Z
dc.date.issued	2020-10
dc.identifier.citation	Bekaii-Saab TS, Valle JW, Van Cutsem E, Rimassa L, Furuse J, Ioka T, et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. 2020 Oct;16(30):2385–99.
dc.identifier.issn	1744-8301
dc.identifier.uri	https://hdl.handle.net/11351/6560
dc.description	FGFR; Colangiocarcinoma; Pemigatinib
dc.language.iso	eng
dc.publisher	Future Medicine
dc.relation.ispartofseries	Future Oncology;16(30)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Conductes biliars - Càncer - Tractament
dc.subject.mesh	Progression-Free Survival
dc.subject.mesh	Cholangiocarcinoma
dc.subject.mesh	/drug therapy
dc.title	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.2217/fon-2020-0429
dc.subject.decs	supervivencia libre de progresión
dc.subject.decs	colangiocarcinoma
dc.subject.decs	/farmacoterapia
dc.relation.publishversion	https://doi.org/10.2217/fon-2020-0429
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Bekaii-Saab TS] Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA. [Valle JW] Division of Cancer Sciences, University of Manchester & Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, The University of Manchester, Manchester, UK. [Van Cutsem E] Department of Oncology, University of Leuven, Leuven, Belgium. [Rimassa L] Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. [Furuse J] Department of Medical Oncology, Kyorin University, Tokyo, Japan. [Ioka T] Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	32677452
dc.identifier.wos	000595834200002
dc.rights.accessrights	info:eu-repo/semantics/openAccess